Table 1.

The STOP-or-NOT trial outcomes, rationales, and potential relationship with the intervention at the time of the trial design. RAAS, renin–angiotensin–aldosterone system; RASI, renin-angiotensin system inhibitor.

Components of the primary outcome at 28 days	Rationale	Strength of the potential relationship with the intervention
Death	-Standardised and patient-centred cardiovascular outcome11	++
Postoperative cardiovascular events	-Standardized and patient-centred cardiovascular outcome -Strategy of RASI management might impact the incidence of postoperative cardiovascular events -Activation of RAAS promotes the occurrence of cardiovascular events, including atrial fibrillation12, 13, 14	+++
Unplanned ICU admission	- Standardised and patient-centred cardiovascular outcome	+++
Acute kidney injury	-Hypotension can decrease renal perfusion -RAAS is a major contributor to glomerular filtration regulation -Activation of RAAS associated with kidney injury15	+++
Postoperative episodes of sepsis	-Standardised and patient-centred cardiovascular outcome -Inhibition of RAAS can increase the risk of hypotension and need for vasopressor if infection develops16 -RASIs associated with immune regulation and might interfere with the risk of developing sepsis17, 18, 19	+
Surgical complications	-Hypotension or use of vasopressors might lead to poor wound healing -Important patient-centred outcome	+
Postoperative respiratory complications	-Standardised and patient-centred cardiovascular outcome -RAAS activation might contribute to lung injury	++